Pfizer Ventures is set to invest $600m in biotechnology, with neuroscience a key focus, bringing the size of its corporate venturing activities to more than $1bn.
Pharmaceutical firm Pfizer yesterday revealed it was planning to invest $600m into biotech and other emerging technologies through newly formed corporate venturing division Pfizer Ventures.
Early-stage neuroscience companies will be a key focus, with approximately $150m allocated to such startups. Initial areas of interest will include neuro-degeneration, neuro-inflammation and neuro-metabolic disorders.
The $600m comes as part of a restructuring effort that combines Pfizer Venture Investments, the company’s existing corporate venturing arm, with research and development equity investment vehicle R&D Innovate.
…
